PS. It was also interesting to read they contacted the SEC in Aug. and were meeting with the SEC within 2 days. Also, that Thomas spoke with Congressional committee members:
"His frustration was so intense that he contacted a House of Representatives committee that was investigating the F.D.A. for its approval of an Alzheimer’s drug from Biogen, called Aduhelm, whose efficacy had been subsequently questioned. Committee staffers got right back to Thomas. “I briefed them,” he told me, with satisfaction."
Both of the above are negatives, but being nothing has happened in 4 months since then could be considered a positive.